Document is current
Any future updates will be listed below
-
Authors
Marino, Roberta
El Aalamat, Yousef
Bol, Vanesa
Caselle, Michele https://orcid.org/0000-0001-5488-142X
Del Giudice, Giuseppe
Lambert, Christophe https://orcid.org/0000-0002-7727-2018
Medini, Duccio
Wilkinson, Tom M. A.
Muzzi, Alessandro https://orcid.org/0000-0002-8635-6424
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
GlaxoSmithKline Biologicals SA
GlaxoSmithKline Biological SA
- License Information
-
More Information
Article History
Received: 14 November 2022
Accepted: 19 August 2024
First Online: 26 October 2024
Competing interests
: R.M. is a PhD student at the University of Turin, with a scholarship from GSK. Y.E.A. was a consultant of XPE Pharma & Science for GSK when the analyses were conducted. V.B., G.D.G., C.L., and A.M. are employees of GSK. D.M. was employed by GSK when the analyses were conducted. G.D.G holds financial equities in GSK. M.C. reports no financial conflict of interest. T.M.A.W. has received grants from AstraZeneca, Synairgen and MyMHealth and fees, reimbursement for travel and meeting attendance from Boehringer Ingelheim, Chiesi, and AstraZeneca, outside of the submitted work, grants from GSK during conduct of the study. In addition, T.M.A.W. has a patent 2018 US Patent 62/479550 – Immunogenic Composition, Use and Methods of Treatment – A novel vaccine to prevent exacerbations of COPD pending to GSK, and a patent 2018 US Patent 62/479562 – Immunogenic Composition, Use and Methods of Treatment – A novel vaccine to prevent exacerbations of COPD pending to GSK and is Founder and Director, MyMHealth Ltd. All authors declare no other financial and non-financial relationships and activities.
